{
    "name": "pegcetacoplan",
    "comment": "Rx",
    "other_names": [
        "Empaveli"
    ],
    "classes": [
        "Complement Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/empaveli-pegcetacoplan-4000158",
    "pregnancy": {
        "common": [
            "Insufficient data regarding use in pregnant females to inform of drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "There are risks to the mother and fetus associated with untreated PNH during pregnancy"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Treatment of pregnant cynomolgus monkeys (28 mg/kg/day SC) (2.9 times human exposure based on AUC) from gestation through parturition resulted in a statistically significant increase in abortions or stillbirths compared with controls"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "PNH in pregnancy associated with adverse maternal outcomes, including worsening cytopenias, thrombotic events, infections, bleeding, miscarriages, and increased maternal mortality, and adverse fetal outcomes, including fetal death and premature delivery"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "May cause embryofetal harm when administered to pregnant females",
                    "Pregnancy testing recommended for females of reproductive potential before treatment",
                    "Advise female patients of reproductive potential to use effective contraception during treatment and for 40 days after last dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if secreted in human milk or whether there is potential for absorption and harm to the infant",
            "There are no data on effects on milk production",
            "Pegcetacoplan is present in milk of lactating monkeys; since many medicinal products are secreted into human milk, and the potential exists for serious adverse reaction in a breastfeeding child, breastfeeding should be discontinued during treatment and for 40 days after the last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Meningococcal infections/sepsis",
                    "description": [
                        "Meningococcal infections/sepsis may occur",
                        "Meningococcal infections may become rapidly lifethreatening or fatal if not recognized and treated early",
                        "Use may predispose individuals to serious infections, especially those caused by encapsulated bacteria, such as ",
                        "Streptococcus pneumoniae, Neisseria meningitidis",
                        " types A, C, W, Y, and B, and ",
                        "Haemophilus influenzae",
                        " type B",
                        "Comply with the most current ACIP recommendations for meningococcal vaccination in patients with complement deficiencies",
                        "Vaccinate against encapsulated bacteria at least 2 weeks before administering the first pegcetacoplan dose, unless the risks of delaying pegcetacoplan outweigh the risk of developing a meningococcal infection",
                        "Vaccination reduces, but does not eliminate, meningococcal infection risk",
                        "Monitor for early signs of meningococcal infections and evaluate immediately if infection is suspected"
                    ]
                },
                {
                    "type": "Risk evaluation and mitigation strategy (REMS)",
                    "description": [
                        "Available only through REMS program",
                        "Prescribers must enroll in the program",
                        "1-888-343-7073 or at ",
                        "www.empavelirems.com"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to pegcetacoplan or to any of the excipients",
                "Patients not vaccinated against certain encapsulated bacteria, unless the risks of delaying pegcetacoplan treatment outweigh risks of developing a bacterial infection with an encapsulated organism",
                "Patients with unresolved serious infection caused by encapsulated bacteria, including ",
                "S pneumoniae, N meningitidis,",
                " and ",
                "H influenzae"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Available only through restricted access program",
                "Infusion-related reactions reported, including systemic hypersensitivity reactions (eg, facial swelling, rash, urticaria); discontinue infusion immediately and provide appropriate treatment, per standard of care, if severe hypersensitivity reaction, including anaphylaxis, occurs; monitor until signs and symptoms resolve"
            ],
            "specific": [
                {
                    "type": "Serious infections caused by encapsulated bacteria",
                    "description": [
                        "May increase risk for serious infections caused by encapsulated bacteria",
                        "All patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies",
                        "Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy",
                        "If vaccination history unknown, administer required vaccines at least 2 weeks before first pegcetacoplan dose",
                        "If immediate therapy with pegcetacoplan indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis",
                        "Closely monitor for infection"
                    ]
                },
                {
                    "type": "Monitoring after discontinuation",
                    "description": [
                        "Closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms (eg, fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events [including thrombosis], dysphagia, erectile dysfunction)",
                        "Monitor for at least 8 weeks to detect hemolysis and other reactions",
                        "If hemolysis, including elevated LDH, occurs, consider restarting treatment "
                    ]
                },
                {
                    "type": "Interference with laboratory tests",
                    "description": [
                        "Drug may interfere with silica reagents in coagulation panels that results in artificially prolonged activated partial thromboplastin time; avoid silica reagents in coagulation panels"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Infusion",
            "percent": "39"
        },
        {
            "name": "site reactions",
            "percent": "29"
        },
        {
            "name": "Infection",
            "percent": "22"
        },
        {
            "name": "Diarrhea",
            "percent": "20"
        },
        {
            "name": "Abdominal pain",
            "percent": "15"
        },
        {
            "name": "Respiratory tract infection",
            "percent": "12"
        },
        {
            "name": "Viral infection",
            "percent": "12"
        },
        {
            "name": "Fatigue",
            "percent": "7"
        },
        {
            "name": "Chest pain",
            "percent": "7"
        },
        {
            "name": "Back pain",
            "percent": "7"
        },
        {
            "name": "Headache",
            "percent": "7"
        },
        {
            "name": "Systemic hypertension",
            "percent": "5"
        },
        {
            "name": "Intestinal ischemia",
            "percent": "5"
        },
        {
            "name": "Biliary sepsis",
            "percent": "5"
        },
        {
            "name": "Hypersensitivity pneumonitis",
            "percent": null
        }
    ]
}